Staphylococcus Or Streptococcus Patents (Class 424/237.1)
-
Patent number: 6984381Abstract: A novel vaccine for immunizing animals against Staphylococcus aureus-induced mastitis is disclosed. The vaccine is comprised of whole killed cells of S. aureus in a dosage effective to immunize an animal against the organism, in combination with a pharmaceutically acceptable carrier.Type: GrantFiled: July 5, 2002Date of Patent: January 10, 2006Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Albert Guidry, Celia O'Brien
-
Patent number: 6979446Abstract: Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein from Staphylococcus aureus, including the active fragments proteins from its fibrinogen binding domain such as Clf40 protein, the Clf33 protein, or ClfA N3, are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. In addition, medical instruments can be treated using the monoclonal antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the antibodies of the present invention are advantageous because they can prevent adherence of the bacteria to host cells by impairing or inhibiting the ability of S. aureus ClfA to bind to fibrinogen or fibrin, and thus can be utilized in methods or treating or preventing staphylococcal inventions.Type: GrantFiled: January 28, 2002Date of Patent: December 27, 2005Assignee: Inhibitex, Inc.Inventors: Joseph M. Patti, Jeff T. Hutchins, Paul Domanski, Pratiksha Patel, Andrea Hall
-
Patent number: 6969616Abstract: The present invention is directed to an enterotoxin adsorbent comprising a compound having a log P (P denotes a partition coefficient in an octanol-water system) value of not less than 2.50 as immobilized on a water-insoluble carrier.Type: GrantFiled: September 25, 2001Date of Patent: November 29, 2005Assignee: Kaneka CorporationInventors: Fumiyasu Hirai, Tamiji Fujimoto, Shigeo Furuyoshi
-
Patent number: 6951653Abstract: Novel vaccines for use against ?-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against ?-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.Type: GrantFiled: May 30, 2001Date of Patent: October 4, 2005Assignee: Regents of the University of MinnesotaInventors: Paul Patrick Cleary, Deborah K. Stafslien
-
Patent number: 6936258Abstract: A negatively-charged Staphylococcus antigen contains amino acids and a N-acetylated hexosamine as a major carbohydrate component. The antigen is common to many coagulase-negative strains of Staphylococcus, including S. epidermidis, S. haemolyticus, and S. hominis. Staphylococcus strains that carry the antigen include many clinically significant strains of Staphylococcus. The antigen and antibodies to the antigen are useful in kits and assays for diagnosing Staphylococcus infection. Vaccines of the antigen and of whole cells that carry the antigen also are disclosed.Type: GrantFiled: March 19, 1999Date of Patent: August 30, 2005Assignee: NABI BiopharmaceuticalsInventors: Viliam Pavliak, Ali Ibrahim Fattom
-
Patent number: 6908619Abstract: The CAMP factor gene of Streptococcus uberis (S. uberis) is described, as well as the recombinant production of CAMP factor therefrom. CAMP factors can be used in vaccine compositions for the prevention and treatment of bacterial infections.Type: GrantFiled: January 21, 1999Date of Patent: June 21, 2005Assignee: University of SaskatchewanInventors: Min Jiang, Andrew A. Potter, Philip Ronald MacLachlan
-
Patent number: 6875853Abstract: The recombinant production of Gap4, a chimeric GapC plasmin binding protein comprising the entire amino acid sequence of the Streptococcus dysgalactiae GapC protein in addition to unique amino acid sequences from the Streptococcus parauberis and Streptococcus agalactiae GapC proteins, is described. Also described is the use of Gap4 chimeric GapC protein in vaccine compositions to prevent or treat streptococcal infections in general and mastitis in particular.Type: GrantFiled: August 27, 2003Date of Patent: April 5, 2005Assignee: University of SaskatchewanInventors: Andrew A. Potter, Jose Perez-Casal, Michael Fontaine
-
Patent number: 6872394Abstract: Pyrogenic toxins, such as staphylococcal enterotoxins, modified in the disulfide loop region are provided. The modified toxins retain useful biological properties but have substantially reduced toxicity compared to the corresponding unmodified native toxin. The native pyrogenic toxins are typically modified by deletions within the disulfide loop region to produce modified enterotoxins having 100-fold or greater decrease in toxicity.Type: GrantFiled: December 1, 1998Date of Patent: March 29, 2005Assignee: Idaho Research Foundation, Inc.Inventor: Gregory I. Bohach
-
Patent number: 6863893Abstract: The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of mammalian species with pneumococcal derived polypeptides that include an alpha helix but exclude a choline binding region as a mechanism for stimulating production of antibodies that protect the vaccine recipient against infection by pathogenic bacterial species. In another aspect the invention provides antibodies against such proteins and protein complexes that may be used as diagnositics and/or as protective/treatment agents for pathogenic bacterial species.Type: GrantFiled: September 25, 2002Date of Patent: March 8, 2005Assignee: MedImmune, Inc.Inventors: Theresa M. Wizemann, Scott Koenig, Leslie S. Johnson
-
Patent number: 6835818Abstract: This invention is directed to mutant SPE-C toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-C toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-C toxin. The mutant SPE-C toxins can form vaccine compositions useful to protect animals against the biological activities of wild type SPE-C toxin.Type: GrantFiled: July 14, 1999Date of Patent: December 28, 2004Assignee: Regents of the University of MinnesotaInventors: Patrick M. Schlievert, Douglas Ohlendorf, David T. Mitchell, Pamala J. Gahr
-
Patent number: 6824997Abstract: A process is disclosed for obtaining a C-polysaccharide cell wall antigen containing not more than about 10% protein from Streptococcus pneumoniae bacteria. The antigen thus obtained is conjugated to a spacer molecule, and the free end of the latter is then conjugated to a chromatographic affinity column. The column is then utilized to purify raw antibodies to S. pneumonia bacteria, thereby producing antigen-specific antibodies. A portion of such antibodies is conjugated to a labeling agent which displays a visible color change upon reaction of the antibodies with their antigenic binding partner and embedded in a first zone of an immunochromatographic assay device. Another portion of such antibodies is bound to the reaction zone of the device which has a view window.Type: GrantFiled: September 16, 1999Date of Patent: November 30, 2004Assignee: BINAX, Inc.Inventors: Norman James Moore, Mary Kathleen Fent, Vladimir Andrei Koulchin, Elena Valentin Molokova
-
Patent number: 6790448Abstract: Isolated peptide sequences and proteins containing these sequences are provided which are useful in the prevention and treatment of infection caused by Gram-positive bacteria. The peptide sequences have been shown to be highly conserved motifs in the surface proteins of Gram-positive bacteria, and these consensus sequences include amino acid sequences such as LPXTG (SEQ ID NO:13), ALKTGKIDIIISGMTSTPERKK (SEQ ID NO:14), VEGAWEKPVAEAYLKQN (SEQ ID NO:15), and EYAGVDIDLAKKIAK (SEQ ID NO:16). By virtue of the highly conserved regions, the sequences and the proteins including these sequences can be utilized to generate antibodies which can recognize these highly conserved motifs and the proteins containing them and thus be useful in the treatment or prevention of a wide range of infections caused by Gram-positive bacteria.Type: GrantFiled: May 8, 2002Date of Patent: September 14, 2004Assignee: The Texas A&M University System UniversityInventors: Yi Xu, Magnus A. O. Hook
-
Patent number: 6783765Abstract: The present invention relates to a process for the preparation of a vaccine against tuberculosis and other intracellular pathogens, this vaccine is targeted against intracellular pathogens, more particularly the pathogen Mycobacterium tuberculosis and Salmonella in this case.Type: GrantFiled: March 23, 2001Date of Patent: August 31, 2004Assignee: Council of Scientific and Industrial ResearchInventors: Javed Naim Agrewala, Naresh Sharma
-
Patent number: 6767536Abstract: Isolated and purified Staphylococcus thioredoxin reductases (TrxB) are provided. Polynucleotides encoding the TrxBs, vectors and host cells containing such polynucleotides are also provided. In addition, antibodies reactive with the TrxBs are provided, as are methods of isolating the TrxBs, as well as methods for producing recombinant TrxBs, using TrxBs for screening compounds for TrxB-modulating activity, and detecting Staphylococcus in a test sample.Type: GrantFiled: March 2, 1999Date of Patent: July 27, 2004Assignee: Ramot at Tel Aviv University Ltd.Inventors: Yair Aharonowitz, Ilya Borovok, Gerald Cohen, Orit Uziel, Leonard Katz
-
Patent number: 6733758Abstract: A new fibrinogen binding protein or polypeptide originating from coagulase negative staphylococci, biotechnological methods for producing the protein or polypeptide having fibrinogen binding activity and a recombinant DNA molecule coding for the protein (or fragments thereof), and micro-organisms (including viruses) containing this recombinant DNA molecule. The present invention further comprises the therapeutic and diagnostic use of the protein and/or DNA, e.g., a diagnostic kit for determining the presence and/or type of coagulase negative staphylococci and a vaccine composition, comprising the protein or DNA.Type: GrantFiled: April 1, 1999Date of Patent: May 11, 2004Inventors: Bengt Guss, Martin Nilsson, Lars Frykberg, Jan-Ingmar Flock, Martin Lindberg
-
Patent number: 6720160Abstract: The present invention involves a method and an immuno-analytical device for the rapid and simultaneous detection of multiple micro-organisms in the biological fluids from milk-producing animals suffering from mastitis. This method is based on a lateral flow immuno-assay technique performed to detect antigens specific for multiple infectious agents which are known to cause and/or be encountered in cases of mastitis. Mastitis is an inflammatory condition affecting the udders of milk-producing animals as a result of microbial infections.Type: GrantFiled: October 11, 2001Date of Patent: April 13, 2004Assignee: Helica BioSystems, Inc.Inventor: Wondu Wolde-Mariam
-
Patent number: 6682745Abstract: The present invention relates to the use of live attenuated bacteria for the manufacture of a vaccine for submucosal administration.Type: GrantFiled: January 27, 2000Date of Patent: January 27, 2004Inventors: Christiaan Antonius Arnoldus Jacobs, Danny Goovaerts
-
Patent number: 6676943Abstract: The present invention relates to the identification and use of a family of human complement C3-degrading proteinases expressed by S. pneumoniae. The proteinase has a molecular weight of about 24 kD to about 34 kD as determined on a 10% SDS polyacrylamide gel. A preferred proteinase of this invention includes the amino acid sequence of SEQ ID NO:2.Type: GrantFiled: October 19, 1999Date of Patent: January 13, 2004Assignee: Regents of the University of MinnesotaInventors: Margaret K. Hostetter, Gary Dunny, Lakshmi S. Nandiwada
-
Patent number: 6663862Abstract: An isolated B1 domain polypeptide of bacterial Protein G which binds a Fab fragment of an IgG but substantially does not bind a Fc fragment of an IgG. Methods for the detection and purification of IgG Fc antibody fragments and Fab antibody fragments using the isolated GB1 domain polypeptides are also disclosed.Type: GrantFiled: June 4, 1999Date of Patent: December 16, 2003Assignee: Duke UniversityInventors: Homme W. Hellinga, David J. Sloan
-
Patent number: 6645515Abstract: Provided is a bacteriostatic composition for salmonellae containing, as the active ingredient, a fermented broth obtained by effecting fermentation with the use of a lactic acid bacteriium belonging to the genus Leuconostoc, Streptococcus or Streptobacterium in a sucrose-containing medium, or a preparation originating in the supernatant obtained by subjecting the fermented broth to fractional precipitation from a water-miscible organic solvent.Type: GrantFiled: May 25, 2001Date of Patent: November 11, 2003Assignee: Meito Sangyo Kabushiki KaishaInventors: Tsuneo Fukata, Takao Ogawa, Kimio Hirose, Kyoji Kito
-
Patent number: 6638516Abstract: The present invention relates to vaccine composition(s) comprising at least two PspAs from strains selected from at least one family, the family being defined by PspAs from strains belonging to the family having greater than or equal to 50% homology in aligned sequences of a C-terminal region of an alpha helical region of PspA. Additionally, the families are further comprised of clades, wherein PspAs from strains which belong to a clade exhibit at least 75% sequence homology in aligned sequences of the C-terminal region of the alpha helix of PspA. Vaccine compositions of the present invention preferably comprise a minimum of 4 and a maximum of 6 strains representing a single clade each, and the at least two PspAs are optionally serologically or broadly cross-reactive.Type: GrantFiled: May 24, 1999Date of Patent: October 28, 2003Assignee: The UAB Research FoundationInventors: Robert S. Becker, David E. Briles, Susan Hollingshead
-
Patent number: 6592876Abstract: PspAs, portions thereof, DNA therefor, and immunological compositions, primers and probes based thereon are disclosed claimed.Type: GrantFiled: September 15, 1995Date of Patent: July 15, 2003Assignee: UAB Research FoundationInventors: David E. Briles, Larry S. McDaniel, Edwin Swiatlo, Janet Yother, Alexis Brooks-Walter
-
Patent number: 6582706Abstract: A vaccine composition is disclosed that comprises polypeptides and fragments of polypeptides containing histidine triad residues or coiled-coil regions, some of which polypeptides or fragments lie between 80 and 680 residues in length. Also disclosed are processes for preventing infection caused by S. pneumoniae comprising administering of vaccine compositions.Type: GrantFiled: December 21, 1999Date of Patent: June 24, 2003Assignee: MedImmune, Inc.Inventors: Leslie S. Johnson, John E. Adamou
-
Publication number: 20030108572Abstract: The present invention provides novel antigenic preparations comprising proteinaceous material associated with adenylate cyclase activity in cultures of B.pertussis, the said preparations being useful as components of acellular whooping cough vaccines. The invention further provides methods for the isolation of such antigenic preparations.Type: ApplicationFiled: December 27, 2002Publication date: June 12, 2003Inventors: Pavel Novotny, Jaroslava Novotny, Juan Antonio Montaraz Crespo, Juraj Ivanyi
-
Patent number: 6565888Abstract: The present invention relates to a sustained release composition for the targeted delivery of biologically active agents to specific tissues and cells. The composition comprises microparticles containing a biocompatible polymer, a water-soluble polymer and a biologically active agent. In one embodiment, the biologically active agent is an antigen or an immunomodulator. In another embodiment, the biologically is a labile agent. The microparticles have a number median diameter of greater than 20 microns upon administration. The water-soluble polymer is present in the sustained released composition in at least about 20% of the dry weight of the microparticle. The sustained release composition provides for the dissolution of the water-soluble polymer of the composition upon hydration, at a much greater rate than the degradation of the biocompatible polymer.Type: GrantFiled: August 23, 2000Date of Patent: May 20, 2003Assignee: Alkermes Controlled Therapeutics, Inc.Inventors: Mark A. Tracy, David S. Scher
-
Patent number: 6544529Abstract: The invention provides antigenic compositions for the vaccination of an animal against bovine mastitis caused by infection with Staphylococcus aureus. The invention also provides methods for stimulating an animal's immune system to respond to antigens derived from selected strains of Staphylococcus aureus by administering the antigenic compositions of the invention to the animal.Type: GrantFiled: September 1, 2000Date of Patent: April 8, 2003Assignee: Maabarot Products Ltd.Inventors: Ze'ev Trainin, Gabriel Leitner, Eugenia Liubashewsky
-
Publication number: 20030032582Abstract: The invention provides nucleic acid molecules encoding membrane-infiltrating polypeptides, host cells that express nucleic acid molecules that encode membrane-infiltrating polypeptides, and membrane-infiltrating polypeptides. Membrane-infiltrating polypeptides have the ability to insert spontaneously into cell membranes, and generally include a membrane-infiltrating amino acid sequence as well as another, selected, amino acid sequence heterologous to the membrane-infiltrating amino acid sequence. The invention also provides methods of treating mammals with cells that contain membrane-infiltrating polypeptides. Further, the invention provides truncated superantigen polypeptide encoding nucleic acid molecules as well as truncated superantigen polypeptides. These truncated superantigens can elicit an anti-tumor immune response without binding MHC II molecules, thus having a limited amount of toxicity.Type: ApplicationFiled: December 17, 1999Publication date: February 13, 2003Inventors: JENNIFER L. WAHLSTEN, SUNDARAM RAMAKRISHNAN, PATRICK M. SCHLIEVERT
-
Patent number: 6503511Abstract: The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of mammalian species with pneumococcal derived polypeptides that include an alpha helix but exclude a choline binding region as a mechanism for stimulating production of antibodies that protect the vaccine recipient against infection by pathogenic bacterial species. In another aspect the invention provides antibodies against such proteins and protein complexes that may be used as diagnositics and/or as protective/treatment agents for pathogenic bacterial species.Type: GrantFiled: April 6, 1999Date of Patent: January 7, 2003Assignee: MedImmune, Inc.Inventors: Theresa M. Wizemann, Scott Koenig, Leslie S. Johnson
-
Patent number: 6476001Abstract: Neural injury may be advantageously treated with CM101, a polysaccharide toxin isolated from Group B &bgr;-hemolytic Streptococcus bacteria. CM1O1 treatment aids in the re-establishment of neuronal connectivity, at least partially inhibits scar formation, and increases the probability of survival during the critical period following injury to the central nervous system. Preexisting neural injuries having scar tissue are ameliorated by surgical excision of the scar tissue in conjunction with administration of CM101.Type: GrantFiled: July 29, 1999Date of Patent: November 5, 2002Assignee: Vanderbilt UniversityInventors: Carl G. Hellerqvist, Artur W. Wamil, Barbara D. Wamil
-
Publication number: 20020150595Abstract: The present invention provides novel antigenic preparations comprising proteinaceous material associated with adenylate cyclase activity in cultures of B.pertussis, the said preparations being useful as components of acellular whooping cough vaccines. The invention further provides methods for the isolation of such antigenic preparations.Type: ApplicationFiled: June 30, 1999Publication date: October 17, 2002Applicant: MILLEN, WHITE, ZELANO & BRANIGAN, P.C.Inventors: PAVEL NOVOTNY, JAROSLAVA NOVOTNY, JUAN ANTONIO MONTARAZ CRESPO, JURAJ IVANYI
-
Patent number: 6447777Abstract: Polymers and polymer conjugates comprising crosslinked Staphylococcal protein A, or crosslinked protein A-superantigen, or crosslinked functional derivatives thereof ranging in size from 12kDa to 1O,OOOkDa are useful in the treatment of autoimmune diseases, such as rheumatoid arthritis and ITP as well as neoplastic diseases. Compositions and pharmaceutical composition comprising chemically crosslinked polymers of protein A alone or protein A and bacterial enterotoxins, optionally further complexed with immunoglobulins and complement components, are disclosed, as are methods for making and using these compositions in the treatment of diseases. Plasma perfusates of protein A immunadsorbent columns in clinical use are shown to act through the leaching of polymers of protein A and protein A-Staphylococcal enterotoxin B having a broad range of molecular masses.Type: GrantFiled: March 28, 1997Date of Patent: September 10, 2002Inventors: David Stephen Terman, Raoul F. Reiser
-
Patent number: 6419932Abstract: Recombinant hybrid streptococcal M protein antigens are provided which elicit protective antibodies against Group A streptococci and prevent rheumatic fever. Recombinant hybrid genes which encode the antigen are provided. Vaccine compositions and methods of administering the compositions are provided to elicit immunity against Group A streptococci.Type: GrantFiled: August 19, 1997Date of Patent: July 16, 2002Assignee: University of Tennessee Research CorporationInventor: James B. Dale
-
Patent number: 6410688Abstract: The invention provides Def1 polypeptides and DNA (RNA) encoding Def1 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing Def1 polypeptides to screen for antibacterial compounds.Type: GrantFiled: August 13, 1999Date of Patent: June 25, 2002Assignee: SmithKline Beecham CorporationInventors: Michael Arthur Lonetto, Richard Lloyd Warren, Daniel Robert Sylvester
-
Patent number: 6379675Abstract: Immunological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.Type: GrantFiled: January 19, 1996Date of Patent: April 30, 2002Assignee: Connaught Laboratories, Inc.Inventors: Robert S. Becker, Robert C. Huebner, Maryann Gray, Karen S. Biscardi, Lorne F. Erdile, Bruno Guy
-
Patent number: 6355255Abstract: Novel vaccines for use against &bgr;-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of strepococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against &bgr;-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.Type: GrantFiled: December 7, 1998Date of Patent: March 12, 2002Assignee: Regents of the University of MinnesotaInventors: Paul Patrick Cleary, Deborah K. Stafslien
-
Patent number: 6346608Abstract: The invention provides mecB polypeptides and polynucleotides encoding mecB polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing mecB polypeptides to screen for antibacterial compounds.Type: GrantFiled: July 24, 2000Date of Patent: February 12, 2002Assignees: SmithKline Beecham Corporation, SmithKline Beecham, PLCInventors: Martin Karl Russel Burnham, Andrew Fosberry, John Hodgson, Deborah Jaworski, Elizabeth Lawlor, Martin Rosenberg, Lisa Kathleen Shilling, Min Wang, Judith Ward
-
Patent number: 6344540Abstract: The invention provides pai polypeptides and DNA (RNA) encoding pai polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing pai polypeptides to screen for antibacterial compounds.Type: GrantFiled: July 28, 1999Date of Patent: February 5, 2002Assignees: SmithKline Beecham Corporation, SmithKline Beecham plcInventors: Michael Terence Black, John Edward Hodgson, David Justin Charles Knowles, Raymond Winfield Reichard, Richard Oakley Nicholas, Martin Karl Russel Burnham, Julie M Pratt, Martin Rosenberg, Judith M Ward, Michael Arthur Lonetto, Patrick Vernon Warren
-
Patent number: 6335424Abstract: The invention provides ribG polypeptides and polynucleotides encoding ribG polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ribG polypeptides to screen for antibacterial compounds.Type: GrantFiled: November 25, 1997Date of Patent: January 1, 2002Assignees: SmithKline Beecham Corporation, SmithKline Beecham PLCInventors: Michael Terence Black, Christine Debouck, Jason Craig Fedon, John Edward Hodgson, Deborah Dee Jaworski, David Justin Charles Knowles, Anna Lisa Kosmatka, Jeffrey Mooney, Richard Oakley Nicholas, Leslie Marie Palmer, Lisa Kathleen Shilling, Robert King Stodola, Min Wang, Richard Lloyd Warren, Yi Yi Zhong
-
Patent number: 6326462Abstract: The invention provides ribH polypeptides and polynucleotides encoding ribH polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ribH polypeptides to screen for antibacterial compounds.Type: GrantFiled: January 27, 2000Date of Patent: December 4, 2001Assignee: SmithKline Beecham CorporationInventors: Christine Debouck, Jason Craig Fedon, Deborah Dee Jaworski, Jeffrey Mooney, Leslie Marie Palmer, Christopher Michael Traini, Min Wang, Richard Lloyd Warren, Yi Yi Zhong
-
Patent number: 6299883Abstract: The invention provides tarF polypeptides and DNA (RNA) encoding tarF polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing tarF polypeptides to screen for antibacterial compounds.Type: GrantFiled: January 28, 1999Date of Patent: October 9, 2001Assignee: SmithKline Beecham CorporationInventors: Alison Frances Chalker, Stephanie Van Horn, Andrew Peter Fosberry, Michael Ovari
-
Patent number: 6290971Abstract: Adjuvant compositions for modulating an immune response to an antigen administered to a host comprise a mineral salt adjuvant and at least one other adjuvant. The compositions provide an adjuvanting effect on an antigen which is greater than the adjuvanting effect attainable by one of the adjuvants alone. An antigen is covalently bonded to a glycolipid analog to provide a discrete molecule which exhibits an enhanced adjuvanting effect on the antigen which is greater than the adjuvanting effect attainable in the absence of such covalent bonding.Type: GrantFiled: February 26, 1997Date of Patent: September 18, 2001Assignee: Aventis Pasteur LimitedInventors: Ali Kandil, Olive A. James, Pele Chong, Michel H. Klein
-
Patent number: 6291178Abstract: A method and apparatus for the preservation of a saliva sample for use in subsequent quantitative chemical assays. The method involves collecting a saliva sample at a location, directly into a specimen cup. The specimen cup contains a predetermined volume of aqueous solution of pH buffered saline and enzymatic inhibitor and is optionally adapted with a constituent compound specific, qualitative test unit.Type: GrantFiled: August 30, 1999Date of Patent: September 18, 2001Inventor: David R. Schneider
-
Publication number: 20010016200Abstract: Disclosed and claimed are: epitopic regions of Pneumococcal Surface Protein C or “PspC”, different clades of PspC, isolated and/or purified nucleic acid molecules such as DNA encoding a fragment or portion of PspC such as an epitopic region of PspC or at least one epitope of PspC, uses for such nucleic acid molecules, e.g., to detect the presence of PspC or of S. pneumoniae by detecting a nucleic acid molecule therefor in a sample such as by amplification and/or a polymerase chain reaction, vectors or plasmids which contain and/or express such nucleic acid molecles, e.g.Type: ApplicationFiled: December 26, 2000Publication date: August 23, 2001Inventors: David E. Briles, Susan K. Hollingshead, Alexis Brooks-Walter
-
Patent number: 6252044Abstract: The invention provides ribB polypeptides and polynucleotides encoding ribB polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ribB polypeptides to screen for antibacterial compounds.Type: GrantFiled: November 25, 1997Date of Patent: June 26, 2001Assignees: SmithKline Beecham Corporation, SmithKline Beecham plcInventors: Michael Terance Black, Lisa Kathleen Shilling, Robert King Stodola, Richard Lloyd Warren, Anna Lisa Kosmatka, Richard Oakley Nicholas, Leslie Marie Palmer, Michael Arthur Lonetto, Jason Craig Fedon, John Edward Hodgson, David Justin Charles Knowles
-
Patent number: 6251385Abstract: Treatment of solid tumors, including their metastases, without radiation, surgery or standard chemotherapeutic agents is described. Ex vivo stimulation of cells, selection of specific V&bgr; subsets of stimulated cells and reinfusion of the V&bgr; subsets of stimulated cells is employed for cancer therapy.Type: GrantFiled: July 22, 1997Date of Patent: June 26, 2001Inventor: David S. Terman
-
Patent number: 6251405Abstract: Immunological compositions and methods for making and using them. The compositions contain an antigen and a lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immurogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.Type: GrantFiled: June 7, 1995Date of Patent: June 26, 2001Assignee: Connaught Laboratories, Inc.Inventors: Robert S. Becker, Robert C. Huebner, Maryann B. Gray, Karen S. Biscardi
-
Patent number: 6222016Abstract: The invention provides spoIIIE polypeptides and DNA (RNA) encoding spoIIIE polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing spoIIIE polypeptides to screen for antibacterial compounds.Type: GrantFiled: July 12, 1999Date of Patent: April 24, 2001Assignee: SmithKline Beecham CorporationInventors: Alison Frances Chalker, Maria Magdalena Zalacain Feliu, James Raymond Brown, Alexander Philip Bryant
-
Patent number: 6203800Abstract: The invention provides gbpA polypeptides and DNA (RNA) encoding gbpA polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing gbpA polypeptides to screen for antibacterial compounds.Type: GrantFiled: March 22, 1999Date of Patent: March 20, 2001Assignee: SmithKline Beecham CorporationInventors: Michael Terence Black, John Edward Hodgson, David Justin Charles Knowles, Raymond Winfield Reichard, Richard Oakley Nicholas, Martin Karl Russel Burnham, Julie M Pratt, Martin Rosenberg, Judith M Ward, Michael Arthur Lonetto, Patrick Vernon Warren
-
Patent number: 6197299Abstract: A soluble antibody conjugate comprising an antibody linked to a structure which is recognized by T-cells and has the ability to direct T-cells to lyse the target cell, which is recognized by the antibody. The conjugate is characterized by the structure being a superantigen. One important mode is a method for the lysis of target cells, wherein the target cells are contacted with a target cell lysis effective amount of the conjugate. The method of lysis is part of a potent treatment regime for cancer, autoimmunity, parasitic infestations and fungal, viral and bacterial infections. The specification also describes modes such as the synthesis of the conjugate and pharmaceutical compositions and their manufacture.Type: GrantFiled: September 16, 1998Date of Patent: March 6, 2001Assignee: Pharmacia & Upjohn ABInventors: Mikael Dohlsten, Eva Åkerblom, Peter A. Lando, Terje Kalland, Gunnar Hedlund